176
Views
11
CrossRef citations to date
0
Altmetric
Research Article

Immunomodulatory effects of rosuvastatin on hepatic ischemia/reperfusion induced injury

&
Pages 555-561 | Received 13 Nov 2009, Accepted 21 Dec 2009, Published online: 02 Feb 2010
 

Abstract

Liver ischemia followed by reperfusion results in liver injury which in turn produces and releases destructive proinflammatory cytokines into the circulation causing subsequent damage to other organs. This remains a significant problem for surgical procedures and liver transplantation. Objective: In this study, we show the effect of rosuvastatin on multiple organ dysfunction induced by hepatic/ischemia reperfusion. Materials and methods: Hepatic ischemia and reperfusion (I/R) injury was induced in rats, and groups of rats were pretreated with oral rosuvastatin. Results: Our study detected the levels of tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), IL-10, and monocyte chemotactic protein 1 (MCP-1) not only in serum but also in liver, lung, kidney intestine, and heart tissues. Rosuvastatin pretreatment appears to protect these organs after hepatic I/R injury through the reduction of proinflammatory cytokines (TNF-α, IL-6, and MCP-1) and stimulation of anti-inflammatory cytokines (IL-10) production. Discussion and conclusion: This is the first report of rosuvastatin immunomodulatory effects on multiorgan dysfunction after hepatic I/R. Our data suggest a therapeutic potential for rosuvastatin in attenuating inflammation and modulating immune response independent of lipid lowering effect.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.